This trial involves 1 different treatment groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
With proper chemotherapy (with or not in remission), most patients are normal and healthy again. These patients still need follow-up, but it is possible that lymphoma can be cured. After complete remission and a relapse-free interval of at least 3 years, the chance of cure is good. But if there remain other diseases at the time of the relapse, there will most likely be another relapse.
In general, lymphoma often features B-symptoms. These can include difficulty in breathing or talking, a rapid heartbeat, loss of appetite, weight loss, swollen lymph nodes in the neck, chest or back. These can also be present in other forms of cancer but are more characteristic of lymphoma than other malignancies. Cancer can also cause bone lesions to be found, but these can also occur in other diseases. Lymphomas can also appear in certain types of blood tests. Recent findings of a full biopsy may be inconclusive. Cancer may also cause fatigue or poor concentration, or a feeling of loss of interest in activities that utilized the body.
The epidemiology of lymphoma is very similar to that of many other common cancers. The risk of developing lymphoma increases with age and, in many communities, appears to be higher among men than women. A previous diagnosis of leukemia, lymphoma or myeloma significantly increases the risk of developing further lymphoma. Exposure to ionizing radiation, in particular to the head and neck region, is also an important risk factor. Non-Hodgkin lymphoma and a B-cell lineage lymphoma seem to be significantly associated with tobacco use. Hodgkin lymphoma is significantly associated with alcohol consumption, especially heavy drinking. Other lifestyle characteristics appear inconclusive, including body mass index, body fat distribution, and physical activity.
About 1,000 new cases a year in the USA are attributable to primary B-Cell lymphoma, which will have been more than a tenth those due to HL in 1992. This underscores the need for better information to be gathered about primary B-Cell lymphomas, since these lymphomas are difficult to diagnose and treat and have poorer treatment responses than HL is. The disparity between the incidence rates for HL and primary B-Cell lymphomas has the potential to skew our present data on the incidence of all lymphomas in the United States.
Most lymphomas are treated with radiation or chemotherapy. In recent years, rituximab has proven effective for some types of lymphomas. Stem cell transplantation therapy has also been recommended for more serious cases and lymphoma proactively.
There was a search of all the studies done that have been published since then on the treatment of lymphoma in order to compile the key questions which to search for further evidence and answer. This resulted in 20 key questions, 13 of which were answered in literature. One key question was new types and dosage of agents to be used for lymphoma treatment. Other key questions include: is the combination of new agents used for lymphoma treatment more effective than single agents; the optimum chemotherapy for Hodgki’s lymphoma; and combination chemotherapy with or without new anti-viral agents for treating all types of lymphomas (Hodgkin’s lymphoma, follicular lymphoma, and diffuse lymphoma).
In the U.S., the highest incidence of non-Hodgkin lymphoma occurs before the age of 40 in men but in women after the age of 50. This is likely due to lower rates of smoking, presumably cigarette-associated causes of nasopharyngeal cancer in men.
Lymphomas are usually very serious and even if treated early, the overall outlook for patients is poor unless they receive more aggressive treatment later on. It is important to treat early rather than late, but then the patient should still be kept on a very regular follow-up, especially if the treatment consisted of chemotherapy and/or radiotherapy. A recent guideline from the UK on lymphoma from the ESCC published in 2013 recommends treating every suspected lymphoma in early stage (Stages I, II, and III but there is no definite answer if it should be Stages I and II in all circumstances as such a disease has never responded to the recommended treatments and the life expectancies are poor~.
The prognosis of classical Hodgkin lymphoma is poor. Nevertheless, about half the patients can be spared from death due to a complete remission. Most will experience excellent quality of life while on treatment. The best way to preserve quality of life involves early and frequent assessment of patients and a close follow-up of the disease during treatment and especially in the long term.
There is currently little evidence-based evidence about the safety of treating people with lymphoma. There may also be safety issues not observed in an experimental setting. It is important to discuss these uncertainties with patients before treatment is advised or with treatment decisions.